ReviewChemical science2020
Structural and process controls of AIEgens for NIR-II theranostics.
Review in Chemical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 268 citations in OpenAlex.
- Emissive Room-Temperature Ionic Liquids Enabled by Dialkylphospholium-Based Tetracyclic Cores with Bulky Counter Anions.JACS Au · 2026Article
- Asymmetric Xanthene with Noncovalent Conformation Locks to Attain High Fluorescence >1500 nm.Journal of the American Chemical Society · 2026Article
- Fluorescence bioimaging of drug nanocarriers based on Förster resonance energy transfer, aggregation-induced emission and aggregation-caused quenching.Acta pharmaceutica Sinica. B · 2026Review
- S···O Conformation Locks Synergistic Alkoxy Chain Engineering of NIR-II Phototheranostic Molecules for Precision Hepatocellular Carcinoma Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- NIR-absorbing organic charge transfer complexes for photothermal antibacterial therapy and wounds healing.Materials today. Bio · 2025Article
- Engineered Substrate-Free Small Molecules for Enhanced Raman Scattering and Photothermal Conversion Efficiency.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Energy Gap Law-Harnessing Design of Highly Second Near-Infrared Emissive 34π-Annulated Porphyrinoids for In Vivo Imaging.Journal of the American Chemical Society · 2025Article
- A Bright Organic Fluorophore for Accurate Measurement of the Relative Quantum Yield in the NIR-II Window.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Rationally designed NIR-II excitable and endoplasmic reticulum-targeted molecular phototheranostics for imaging-guided enhanced photoimmunotherapy of triple-negative breast cancer.Journal of nanobiotechnology · 2025Article
- Exploring the sensing properties of pH-sensitive carbazole-based AIE emitters and their applications in paper strip sensing.RSC advances · 2025Article
- Nanoagent-Mediated Photothermal Therapy: From Delivery System Design to Synergistic Theranostic Applications.International journal of nanomedicine · 2025Review
- Integrating Ultrabright Polymer Dots and Stereo NIR-II Imager for Assessing Anti-Angiogenic Drugs in Oral Cancer Model.Journal of cellular and molecular medicine · 2025Article
- Advancing Cancer Treatment: Innovative Materials in PDT and Diagnostic Integration.International journal of nanomedicine · 2025Review
- Shedding light on vascular imaging: the revolutionary role of nanotechnology.Journal of nanobiotechnology · 2024Review
- Suppressing ROS Production of AIE Nanoprobes by Simple Matrices Optimization for CNS Cell Observation and Minimized Influence of Cytoskeleton Morphology.Chemical & biomedical imaging · 2024Article
- Aggregation-induced emission luminescence for angiography and atherosclerotic diagnosis.iScience · 2024Review
- Julolidinyl aza-BODIPYs as NIR-II fluorophores for the bioimaging of nanocarriers.Acta pharmaceutica Sinica. B · 2024Article
- High-performance near-infrared OLEDs maximized at 925 nm and 1022 nm through interfacial energy transfer.Nature communications · 2024Article
- Understanding the Novel Approach of Nanoferroptosis for Cancer Therapy.Nano-micro letters · 2024Review
- Hierarchical Self-Assembly Molecular Building Blocks as Intelligent Nanoplatforms for Ovarian Cancer Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aggregation-induced emission (AIE) is a cutting-edge fluorescence technology, giving highly-efficient solid-state photoluminescence. Particularly, AIE luminogens (AIEgens) with emission in the range of second near-infrared window (NIR-II, 1000-1700 nm) have displayed salient advantages for biomedical imaging and therapy. However, the molecular design strategy and underlying mechanism for regulating the balance between fluorescence (radiative pathway) and photothermal effect (non-radiative pathway) in these narrow bandgap materials remain obscure. In this review, we outline the latest achievements in the molecular guidelines and photophysical process control for developing highly efficient NIR-II emitters or photothermal agents with aggregation-induced emission (AIE) attributes. We provide insights to optimize fluorescence efficiency by regulating multi-hierarchical structures from single molecules (flexibilization) to molecular aggregates (rigidification). We also discuss the crucial role of intramolecular motions in molecular aggregates for balancing the functions of fluorescence imaging and photothermal therapy. The superiority of the NIR-II region is demonstrated by fluorescence/photoacoustic imaging of blood vessels and the brain as well as photothermal ablation of the tumor. Finally, a summary of the challenges and perspectives of NIR-II AIEgens for
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.